A Study for Treatment of Paroxysmal Atrial Fibrillation (PAF) by Pulsed Field Ablation (PFA) System With Irreversible Electroporation (IRE)

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 272 participants.

Also called NCT04524364

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 272 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04524364
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Austria, Belgium, Canada, Croatia, Czechia, France, Italy, Lithuania (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04524364. Allocation not applicable; no masking; primary purpose treatment. Start 2020-08-23 (actual); primary completion 2023-05-09 (actual). Results posted on 2024-05-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study for Treatment of Paroxysmal Atrial Fibrillation (PAF) by Pulsed Field Ablation (PFA) System With Irreversible Electroporation (IRE)
Acronym
inspIRE
Intervention (Device)
Pulsed Field Ablation (PFA) Therapy
Lead sponsor
Biosense Webster, Inc. (class: industry)

Record details

Record id
cardio:ct-nct04524364
Content hash
21e1e470a617a152c58cafa10d628e971c46185c6375ad0530442e2c7d66505f